Publication of Prospectus

RNS Number : 9284Q

WideCells Group PLC

22 February 2019

 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES IN WIDECELLS GROUP PLC OR ANY OTHER ENTITY IN ANY JURISDICTION. NEITHER THIS ANNOUNCEMENT NOR THE FACT OF ITS DISTRIBUTION SHALL FORM THE BASIS OF, OR BE RELIED ON IN CONNECTION WITH, ANY INVESTMENT DECISION IN RESPECT OF WIDECELLS GROUP PLC.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 596/2014 ("MAR").

22 February 2019

WIDECELLS GROUP PLC ("WideCells Group" or the "Group")

Publication of Prospectus

WideCells Group PLC, the healthcare services group focussed on providing stem cell services and ground-breaking insurance for stem cell treatment, announces that the prospectus (the "Prospectus") regarding the further issuance of Convertible Bonds, convertible into ordinary shares of £0.0025 each in the Group, pursuant to the financing agreement entered into by the Group and the European High Growth Opportunities Securitization Fund (see RNS dated 6 November 2018), has been approved by the UK Listing Authority. The Prospectus is not, subject to certain exceptions, available (whether through the Company's website or otherwise) to shareholders in the United States or any of the Excluded Territories.

The Prospectus will be submitted to the National Storage Mechanism and will be available for inspection at http://www.morningstar.co.uk/uk/nsm following publication.  It is also expected to be made available on the Group's website (details below) later today.

All capitalised terms in this announcement have the meanings given to them in the Prospectus, unless otherwise defined herein.

Market Abuse Regulation (MAR) Disclosure - Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

**ENDS**

For further information, please visit the Company's website www.widecellsgroup.com or contact:

Shard Capital Partners LLP	Broker - Damon Heath & Erik Woolgar	Tel: [phone]
St Brides Partners Limited	PR - Melissa Hancock & Isabel de Salis	Tel: [phone]

 

END

 

 

PDIDLLFLKLFZBBV